குழந்தை நரம்பியல் புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from குழந்தை நரம்பியல் புற்றுநோயியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In குழந்தை நரம்பியல் புற்றுநோயியல் Today - Breaking & Trending Today

Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN...)


Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN.)
THOUSAND OAKS (dpa-AFX) - The week that just passed by saw a couple of stocks belonging to the healthcare sector record triple-digit gains and nearly a dozen managing to log gains in excess of 50 percent, thanks to positive clinical trial readouts.
Greenwich LifeSciences Inc. (GLSI), which closed out the week at $56, delivering over 890%, was the top gainer of the week, following promising five year-data related to its drug candidate GP2 in a phase II clinical trial in HER2 positive women with operable breast cancer.
Curis Inc. (CRIS) closed the week at $7.89, recording a weekly gain of nearly 320%, on the back of positive preliminary data from its ongoing phase I study of CA-4948 monotherapy in patients with relapsed or refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes. ....

United States , Hong Kong , Abbvie Lupron , Myovant Relugolix , Roche Rituxan , Cellectar Biosciences , Astrazeneca Zoladex , Gossamer Bio Inc , Arvinas Inc , Zai Lab , Advisory Committee , Cellectar Biosciences Inc , Curis Inc , Greenwich Lifesciences Inc , Therapeutics Inc , Moderna Inc , Xenetic Biosciences Inc , Macrogenics Inc , Emergency Use Authorization Of Moderna Inc , Tv Therapeutics Inc , Myovant Sciences Ltd , Life Sciences Group Inc , Amgen Inc , Biocryst Pharmaceuticals Inc , International Symposium On Pediatric Neuro , Acute Myeloid Leukemia ,